On Friday, Lumibird suffered one of the biggest declines on the Paris market after re-evaluating its financial targets for 2024 just a few weeks before the end of the financial year.

The laser technology specialist now expects annual sales of at least 200 million euros, i.e. organic growth of at least 5%, below the 8% announced at the beginning of the year and confirmed at the end of October.

In a press release, the Group cites deferred deliveries due to technical delays in the qualification and production of certain products, as well as postponed orders for regulatory reasons or due to scheduling adjustments by customers.

The company also states that it suffered from persistent unfavorable currency effects in Q4.

The downward revision of its annual sales forecast will have an automatic impact on its operating margin (Ebitda), now expected to exceed 17%, i.e. below the 20% previously announced.

At 2.20 pm, Lumibird's share price fell by almost 15% in a slightly rising Paris market (+0.4% on average). Since the beginning of the year, the stock has fallen by more than 32%.

The result of the 2017 merger between Quantel and Keopsys, Lumibird manufactures high-performance lasers for scientific (research laboratories, universities), industrial (production, defense/space, Lidar sensors) and medical (ophthalmology, ultrasound diagnostics) applications.

Copyright (c) 2023 CercleFinance.com. All rights reserved.